This randomized, double-blind, placebo-controlled study was conducted to investigate whether alfuzosin 10 mg once daily improves the maximum flow rate (Q max ) and lower urinary tract symptoms (LUTS) of benign prostatic hyperplasia (BPH) after 1 week and 1 month of treatment. A total of 372 men aged X50 years with symptomatic BPH received alfuzosin or placebo for 28 days. Q max increased significantly from baseline at day 8 with alfuzosin (Po0.001 versus placebo); this improvement was evident within 24 h after the first dose and was maintained at day 29. LUTS improved from baseline with alfuzosin at day 8 (P ¼ 0.07 versus placebo) and day 29 (P ¼ 0.003 versus placebo). Alfuzosin 10 mg once daily exhibits a rapid onset of action, with improvements in Q max and LUTS maintained through 1 month of treatment.
Introduction
Uroselective a 1 -adrenergic blockers, such as alfuzosin, are recommended as first-line treatment for the management of uncomplicated, moderate-to-severe, lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH). 1 Blockade of a 1 -adrenoceptors is associated with decreased smooth muscle contraction in various organs. 2 In the urogenital tract, a 1 -blockers improve urinary flow by blocking the stimulation of a 1 -adrenoceptors, thereby preventing the contraction of smooth muscle within the prostate, urethra, bladder neck and detrusor muscle. 3 Alfuzosin has been available in Europe since 1988 in immediate-release (2.5 mg three times per day (t.i.d.)) and sustained-release (5 mg twice per day (b.i.d.)) formulations. More recently, a new extended release one-daily formulation, alfuzosin 10 mg q.d., became available in Europe and the United States to improve patient compliance and tolerability. Results from trials with immediate-and sustained-release alfuzosin consistently demonstrated a significant decrease in the severity of LUTS, an increase in the maximum flow rate (Q max ), a decrease in residual urine volume and a decrease in the bother associated with LUTS. [4] [5] [6] [7] In one of these trials, men with symptomatic BPH (N ¼ 289) exhibited a fivepoint decrease in the total International Prostate Symptom Score (IPSS) versus baseline (Po0.01) within 3 months of alfuzosin 2.5 mg t.i.d. treatment. 5 Comparable improvements were also observed within the first 28 days of therapy with alfuzosin 10 mg q.d. In a pooled analysis of three randomized, double-blind, placebocontrolled trials in men with LUTS secondary to BPH (N ¼ 473), treatment with alfuzosin 10 mg q.d. resulted in a change from baseline in the IPSS of 44 points (Po0.001 versus placebo). 8 The onset of action of alfuzosin 10 mg q.d. appeared to be rapid, with a significant increase from baseline in Q max (Po0.005) at the first clinic visit at 14 days. 8 A more recent investigation suggested that the onset of therapeutic action begins within hours after the first dose of alfuzosin 10 mg q.d. 9 Eight hours after the first dose of alfuzosin 10 mg q.d. in men with BPH who were known to respond to a 1 -blockers (N ¼ 34), significant increases in Q max were observed (mean increase of 3.2 ml/s compared with 1.1 ml/s for placebo; P ¼ 0.002). 9 To better determine the onset of symptom relief with alfuzosin 10 mg q.d. in men with symptomatic BPH, we conducted a short-term, randomized, controlled clinical trial. For this investigation, we used both objective uroflowmetry measures as well as symptom scores derived from a validated, 'acute' version of the IPSS (Acute IPSS). 10, 11 The Acute IPSS poses the same questions as the standard IPSS, but patients are asked to report their symptoms during the preceding 1 week rather than the preceding 1 month. We also examined improvements in LUTS after 28 days of treatment using the same 7-day Acute IPSS to assess the maintenance of the therapeutic response.
Methods
This was a multicentered, randomized, double-blinded, placebo-controlled, parallel-group, clinical trial in men with symptomatic BPH. Men aged X50 years with LUTS suggestive of BPH, including a history (X6 months) of storage (e.g., increased daytime frequency, urgency and nocturia) and/or voiding symptoms (e.g., difficulty initiating micturition, feeling of incomplete voiding, impaired quality of stream and interruption of stream). Inclusion criteria were an IPSS of X13 points (score range 0-35, with higher scores indicating more severe LUTS) and an IPSS bother score of X3 points (score range 0-6, with a higher score indicating greater bother). The Q max was required to be between 5 and 12 ml/s, with a voided volume of X150 ml and post-void residual of p350 ml by abdominal ultrasonography. Prostate volume was evaluated in all patients within 12 months before or at study entry. Exclusion criteria included conditions that could affect urinary functioning, such as Parkinson's disease, multiple sclerosis, poorly controlled diabetes, severe heart failure, stroke, recent myocardial infarction (within the last 5 months) or concomitant lower urinary tract disease (including neurogenic bladder dysfunction, urethral stenosis, isolated bladder neck disease, bacterial prostatitis or acute urinary tract infection). Patients were excluded from enrollment if they had previous prostatic surgery or radiation therapy, an endoscopic procedure within 1 month of screening (day À28), spontaneous urinary retention during the preceding 12 months, an ongoing episode of urinary retention requiring an indwelling catheter, postural hypotension, or syncope or were known non-responders to previous a 1 -blocker therapy at an adequate dose for symptomatic BPH. Furthermore, patients reporting concomitant use of medications that might alter voiding patterns, including a-blockers within the last month, androgens within 3 months, antiandrogens, 5a-reductase inhibitors and/or luteinizing hormone-releasing hormone analogs were not eligible. Patients with evidence of clinically relevant biochemical abnormalities or a serum prostate-specific antigen level of 410 ng/ml were excluded. For patients with a serum prostate-specific antigen level of between 4 and 10 ng/ml, prostate cancer had to be excluded to the satisfaction of the investigator before patient enrollment.
At screening (day À28), patient eligibility was determined and informed consent was signed. Patient history and demographic information was obtained, uroflowmetry and transabdominal ultrasonography were conducted, and relevant records of transrectal ultrasonography were reviewed. The Acute IPSS and IPSS bother question were also completed. Samples were collected for laboratory testing, including complete blood counts, blood chemistry and urinalysis, and a 12-lead electrocardiogram (ECG) was performed. During the run-in phase (day À28 to day 0) patients received one tablet of placebo per day on an open-label basis. At the end of the run-in phase, eligible patients were randomly assigned (1:1) to alfuzosin or a matching placebo tablet, to be taken once daily after the evening meal, at approximately 0700 h or as late as possible. Baseline (day 1) evaluations included uroflowmetry, the Acute IPSS, the IPSS bother question and the BPH Impact Index. 12 Supine and standing blood pressure (BP) were measured to detect postural hypotension. Patients were given a 7-day supply of study medication (alfuzosin or placebo). During the double-blind treatment period, patients underwent evaluations on days 2, 8 and 29.
On days 2 and 8, patients returned to the study clinic between 0700 and 0800 h with a full bladder for uroflowmetry, supine and standing BP and heart rate measurements, and recording of any adverse events. On day 8, patients completed the Acute IPSS and bother question and were given the remaining 3-week supply of study medication. On day 29, or at the final study visit for patients discontinuing treatment, a full set of clinical and laboratory evaluations were conducted. The primary study objective was to investigate whether alfuzosin 10 mg q.d. exerts any beneficial effect on urodynamic and symptomatic parameters of BPH at day 8. The primary end points were the change from baseline at day 8 in Q max and the total Acute IPSS. The main secondary end point was the mean change from baseline at day 29 in the IPSS bother score. Other secondary end points were the change from baseline at days 2 and 29 in Q max and the change from baseline at day 29 in the total Acute IPSS and the BPH Impact Index. Safety was assessed based on clinical, laboratory and cardiovascular measures, as well as monitoring of patient-reported adverse events (AEs). Treatment-emergent adverse events (TEAEs), defined as AEs occurring between the start of treatment and 48 h (i.e., five halflives) after administration of the last dose of study medication, were examined among patients who received at least one dose of study medication (i.e., the safety population).
Based on previous placebo-controlled clinical trials of alfuzosin, [13] [14] [15] [16] [17] and with power set at 80%, it was estimated that at least 171 patients per treatment group were required to detect a 2-point difference in Acute IPSS between alfuzosin-and placebo-treated patients. The primary analysis was conducted on the intent-to-treat (ITT) population (defined as all patients who had been randomized, took at least one dose of study medication, and provided efficacy data that contributed to at least one efficacy analysis), with missing values imputed using the last observation carried forward method. The study also examined end point measures derived from the per-protocol population (defined as patients with no missing Q max and Acute IPSS values who took medication appropriately and showed no evidence of any fundamental protocol violations).
Analysis of covariance was used to evaluate day 8 Acute IPSS and Q max values, with baseline values for each of these assessments as the covariates. The baseline value for all variables was defined as the last observation before administration of study drug. All statistical tests were two-sided, and to maintain an overall error rate of 0.05 with analysis of the primary end points, the adjusted P-value was set at 0.025. The P-value for analysis of the main secondary end point (IPSS bother score at day 29) was set at 0.05.
Results
A total of 372 men were randomized to treatment; 186 to alfuzosin and 186 to placebo. Baseline demographic and Onset of action of alfuzosin 10 mg q.d. in BPH MI Resnick and CG Roehrborn disease characteristics were similar between the two treatment groups (Table 1) . Ten (5.4%) patients in the alfuzosin group and seven (3.8%) patients in the placebo group discontinued the treatment, prematurely. Good Clinical Practice violations at one site resulted in nine patients (five alfuzosin patients and four placebo patients) being excluded from the efficacy analyses. Patients in the ITT population who received treatment with alfuzosin had a significantly greater mean improvement in Q max from baseline at day 8 (1.92 ml/s) than patients in the placebo group (0.39 ml/s) (Po0.001; Figure 1 ). An increase in Q max was evident within 24 h of the first dose of alfuzosin (1.58 versus 0.71 ml/s in the placebo group; Po0.021) and persisted on day 29 (1.76 versus 0.36 ml/s for the placebo group; Po0.001; Figure 1 ). The results were comparable for the perprotocol population (Po0.001).
At day 8, patients in the ITT population who received treatment with alfuzosin had a mean change in the total Acute IPSS of À3.4 points compared with À2.7 points in the placebo group (P ¼ 0.071; Figure 2 ). At day 29, the difference between the two groups was statistically significant (alfuzosin, À4.5 points; placebo, À3.1 points; P ¼ 0.003). In the per-protocol population, however, symptom improvement from baseline at day 8 with alfuzosin (mean change from baseline in Acute IPSS of À3.6 points) was significantly greater than with placebo (mean change from baseline in Acute IPSS of À2.6 points) (P ¼ 0.043).
For both the ITT and per-protocol populations, comparable mean changes from baseline at day 29 in the IPSS bother score, a measure of BPH-related quality of life (QoL), were seen with alfuzosin (À0.7) and placebo (À0.6) (P ¼ 0.125). At day 29, a significantly greater reduction from baseline in the BPH Impact Index was observed in the ITT population with alfuzosin (À0.9) than with placebo (À0.5) (P ¼ 0.02).
Overall, the number of patients who experienced TEAEs was similar between the two treatment groups (alfuzosin, 46/185 (24.9%); placebo, 43/185 (23.2%)), with most TEAEs of mild or moderate severity. The most frequently reported TEAE was dizziness (5.6%) in the alfuzosin group and orthostatic hypotension (1.6%) in the placebo group ( Table 2 ). The incidence rates of vasodilatory and sexual function AEs were low and comparable in the two treatment groups ( Table 2) . No clinically significant changes in BP were observed after the first dose of alfuzosin or during the remainder of the study. No clinically meaningful trends were observed in clinical laboratory tests, vital signs, the physical examination, the digital rectal examination, or ECG results. One patient from the alfuzosin group reported a serious AE (non-insulin-dependent diabetes mellitus) that was judged by the investigator as unrelated to study treatment. No patient discontinued the study because of a serious AE. Non-serious AEs led Onset of action of alfuzosin 10 mg q.d. in BPH MI Resnick and CG Roehrborn to the discontinuation of treatment in three alfuzosin patients (headache, palpitations, confusional state and dizziness) and one placebo patient (urinary frequency).
Discussion
Although rapid, measurable effects on Q max following alfuzosin administration are well established, the timing of symptomatic relief has not been as extensively studied. 9 Measurement of early symptom relief in controlled clinical trials has generally not employed a validated symptom assessment instrument that evaluates symptom severity during the preceding days rather than months. The current investigation addressed this issue by using the validated Acute version of the IPSS, 10, 11 allowing us to evaluate symptom relief after 1 week of alfuzosin therapy. Our data suggest that rapid symptom relief occurs with alfuzosin 10 mg q.d. treatment. After 7 days of alfuzosin treatment, Q max significantly increased from baseline, with increases observed within 24 h after administration of the first alfuzosin dose and persisting through day 29. The total Acute IPSS also improved at day 8 and 29 with alfuzosin treatment. These improvements in Q max and LUTS with alfuzosin were associated with a significant improvement in BPH-related quality of life, as assessed with the BPH Impact Index.
In a pooled analysis of three randomized, placebocontrolled, clinical trials of alfuzosin (N ¼ 693), a significant increase from baseline in Q max was seen 14 days following the first alfuzosin dose when compared with placebo. 8 In addition, data from a small trial (N ¼ 34) showed that Q max significantly increased from baseline as soon as 8 h after administration of the first alfuzosin dose. 16 Our present findings, which are based on a larger patient sample, confirm this previous report. Men in the present study exhibited a mean improvement from baseline in Q max of 1.58 ml/s within 24 h after the first dose of alfuzosin versus only 0.71 ml/s with placebo. After 7 and 28 days of alfuzosin treatment, the increases from baseline in Q max were sustained. Sustained efficacy and symptom improvement with alfuzosin therapy for up to 3 years is well established. [16] [17] [18] The profile of rapid and sustained efficacy with alfuzosin therapy, paired with good tolerability and safety, has positive implications for patient compliance. AEs observed in the present study were similar to those reported previously with alfuzosin. 8 The overall incidence of TEAEs was similar with alfuzosin and placebo. The low incidence of sexual side effects with alfuzosin is in agreement with the results of previous clinical trials. 8 In conclusion, improvements in Q max , as assessed with uroflowmetry, are evident within 24 h of the first dose of alfuzosin 10 mg q.d. Relief of BPH symptoms, as measured with the Acute IPSS scale, is observed after 7 days of alfuzosin treatment. These improvements are maintained through day 28 of alfuzosin treatment. The rapid onset and lasting nature of BPH symptom relief with alfuzosin treatment, together with its good cardiovascular and sexual tolerability, are likely to have a positive effect on patients' adherence to treatment in the initial phases of therapy and their willingness to continue long-term treatment for BPH symptom management.
